photo of woman looking at medical bills

Migraines are painful, but if you need ongoing treatment, your pocketbook might also suffer. Research shows people with chronic migraine can expect to spend $8,500 to $9,500 a year on treatment. 

Infusion therapy, which is a type of treatment that delivers medicines straight into your bloodstream, can be particularly expensive. The good news is there are ways to help you manage the cost of this treatment. 

How Much Does Infusion Therapy Cost?

The cost depends on the type of infusion therapy you get and if you have insurance.

Cost for eptinezumab-jjmr (Vyepti) infusions

At this time, a biologic medicine called eptinezumab-jjmr (Vyepti) is the only approved infusion therapy to avoid a migraine. The list price of eptinezumab-jjmr is $1,940.07 for one vial that contains 100 milligrams (mg) in 1 milliliter (mL). 

Most doctors recommend 100 mg every three months. That means if you pay out of pocket, this therapy will cost you about $7,760.28 a year. 

There also may be extra fees, depending on your health care provider and where you get the infusion. If you don’t have any insurance, you may have to pay the full price. 

Cost for dihydroergotamine (DHE) infusion

Another type of infusion therapy, called dihydroergotamine (DHE), is sometimes used to treat active migraine symptoms. It’s usually given in a hospital, emergency department, or outpatient infusion center. 

One study found the average cost depends on where you get your infusion. If you get a DHE infusion at an:

  • Outpatient infusion center, you may pay about $6,318
  • Inpatient setting, you may pay $9,995

Does Insurance Cover the Cost of Infusion Therapy?

Insurance companies may cover all or just some of the cost of your infusion therapy.  It depends on your specific plan.

If your insurance company denies your claim and refuses to pay for your infusion treatment, you can make an appeal. 

What About Medicare and Medicaid?

Medicare is a government health insurance program for people ages 65 and older or those with a disability.

Medicare and infusion therapy costs 

If you have Medicare, you may be able to get coverage for infusion therapy through Medicare Part B, which is  the "medical insurance" portion of the plan. With Medicare Part B, you might have to pay a 20% coinsurance payment after you meet your deductible. 

If you have a supplemental plan or a Medicare Advantage Plan, your costs may be lower.

Medicaid infusion therapy costs

With Medicaid, a government program that provides health coverage to low-income people, you may be able to get infusion therapy at little to no cost. Your out-of-pocket fees will likely depend on your household income and the state you live in.

Assistance Programs and Resources

There are programs that can help lower the cost of your infusion therapy like eptinezumab-jjmr (Vyepti).

Manufacturer program

The manufacturer of eptinezumab-jjmr (Vyepti) offers a copay assistance plan for people with private health insurance. With this program, you may qualify for infusions at a low cost or no cost. 

Other programs

But if you don’t qualify for this assistance program, you may still be able to get help with the cost of your medicine. 

The HealthWell Foundation also offers financial help for people who need migraine medicines, including expensive biologic drugs. 

The Patient Advocate Foundation is another resource that can help you navigate insurance denials, appeals, and other common roadblocks to migraine care.

Show Sources

Photo Credit: RichLegg/Getty Images

SOURCES:

American Journal of Managed Care: "Concomitant Medical Conditions and Total Cost of Care in Patients With Migraine: A Real-World Claims Analysis."

Premier Health: "Infusion Therapy for Migraine Pain."

Vyepti: "How Vyepti Works," "Pricing and Support."

Barrow Neurological Institute: "Dihydroergotamine Infusion Overview."

Journal of Pain Research. "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations."

Pediatric Neurology: "Outcome and Cost of Inpatient Hospitalization for Intravenous Dihydroergotamine Treatment of Refractory Pediatric Headache."

National Association of Insurance Commissioners: "How to Appeal Denied Claims."

Healthcare.gov: "Appealing a health plan decision."

Medicare.gov: "Parts of Medicare," "Medicaid." 

Neruology: "Developing an Outpatient Infusion Center for Treatment of Pediatric Headache Disorders Redirects Point of Care and Decreases Heath Care Costs."